Nurix Therapeutics, Inc. NRIX Stock-Based Comp
Stock-Based Comp at other companies
Other financials
Where this comes from
Reported directly by Nurix Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:ShareBasedCompensation.
The official record: Nurix Therapeutics, Inc.’s 10-Q, filed April 8, 2026, on SEC EDGAR. View the filing →
Ask your AI about Nurix Therapeutics, Inc.'s stock-based comp.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Nurix Therapeutics, Inc.'s stock-based comp?
- Nurix Therapeutics, Inc. (NRIX) reported stock-based comp of $9.4M in Q4 2025.
- How has Nurix Therapeutics, Inc.'s stock-based comp changed year-over-year?
- Nurix Therapeutics, Inc.'s stock-based comp increased by 7.8% year-over-year, from $8.72M to $9.4M.
- What is the long-term trend for Nurix Therapeutics, Inc.'s stock-based comp?
- Over 4 years (2021 to 2025), Nurix Therapeutics, Inc.'s stock-based comp has grown at a 24.5% compound annual growth rate (CAGR), from $15.8M to $37.97M.
- What does stock-based comp mean?
- Total non-cash stock-based compensation expense for equity awards (RSUs, options, ESPP), added back to net income in cash flow reconciliation.